Tags

Type your tag names separated by a space and hit enter

Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A(2) in patients with stable angina.
Nutr Metab Cardiovasc Dis. 2014 Apr; 24(4):434-9.NM

Abstract

BACKGROUND AND AIMS

Increased consumption of omega-3 polyunsaturated fatty acids (PUFA) together with lifestyle measures and medications is recommended for the prevention of cardiovascular diseases. However, the exact mechanisms underlying observed benefits are not well defined. To this aim, we evaluated the effects of omega-3 PUFA in stable coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI) on lipoprotein associated phospholipase A2 (Lp-PLA2) mass and activity and their relation to oxidized low-density lipoproteins (oxy-LDL).

METHODS AND RESULTS

In a prospective, double-blind, placebo-controlled, randomized study Lp-PLA2, oxy-LDL, myeloperoxidase and interleukin-6 were determined at baseline, 3-5 days and 30 days during administration of omega-3 PUFA 1 g/day (n = 30) or placebo (n = 24). Treatment with omega-3 PUFA resulted in reduction of Lp-PLA2 mass by 10.7%, activity by 9.3 (p = 0.026 for both) and oxy-LDL by 10.9% (p = 0.014) at 30 days, with no change in myeloperoxidase and interleukin-6. Compared with placebo, patients receiving omega-3 PUFA had lower Lp-PLA2 mass by 9.42%, activity by 9.2 (p = 0.041 for both) and oxy-LDL by 12.3% (p = 0.10) after one month, but not at 3-5 days. There were no correlations between Lp-PLA2 and both myeloperoxidase and oxy-LDL throughout the study. The multivariate model showed that only treatment with omega-3 PUFA and baseline myeloperoxidase levels were independent predictors of Lp-PLA2 mass changes at one month (R(2) = 0.37, P = 0.005).

CONCLUSIONS

Administration of omega-3 PUFA can decrease Lp-PLA2 in patients with stable angina undergoing PCI. This novel effect may contribute to the benefits derived from omega-3 PUF.

Authors+Show Affiliations

Department of Coronary Disease, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Department of Experimental Cardiac Surgery and Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; John Paul II Hospital, Krakow, Poland. Electronic address: ggajos@szpitaljp2.krakow.pl.Department of Coronary Disease, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; John Paul II Hospital, Krakow, Poland.Department of Coronary Disease, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; John Paul II Hospital, Krakow, Poland.Department of Coronary Disease, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; John Paul II Hospital, Krakow, Poland.Department of Coronary Disease, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; John Paul II Hospital, Krakow, Poland.Department of Experimental Cardiac Surgery and Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; John Paul II Hospital, Krakow, Poland.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24555913

Citation

Gajos, Grzegorz, et al. "Polyunsaturated Omega-3 Fatty Acids Reduce Lipoprotein-associated Phospholipase A(2) in Patients With Stable Angina." Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, vol. 24, no. 4, 2014, pp. 434-9.
Gajos G, Zalewski J, Mostowik M, et al. Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A(2) in patients with stable angina. Nutr Metab Cardiovasc Dis. 2014;24(4):434-9.
Gajos, G., Zalewski, J., Mostowik, M., Konduracka, E., Nessler, J., & Undas, A. (2014). Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A(2) in patients with stable angina. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, 24(4), 434-9. https://doi.org/10.1016/j.numecd.2013.09.011
Gajos G, et al. Polyunsaturated Omega-3 Fatty Acids Reduce Lipoprotein-associated Phospholipase A(2) in Patients With Stable Angina. Nutr Metab Cardiovasc Dis. 2014;24(4):434-9. PubMed PMID: 24555913.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A(2) in patients with stable angina. AU - Gajos,Grzegorz, AU - Zalewski,Jaroslaw, AU - Mostowik,Magdalena, AU - Konduracka,Ewa, AU - Nessler,Jadwiga, AU - Undas,Anetta, Y1 - 2013/11/01/ PY - 2013/03/03/received PY - 2013/08/06/revised PY - 2013/09/09/accepted PY - 2014/2/22/entrez PY - 2014/2/22/pubmed PY - 2014/12/15/medline KW - Atherosclerosis KW - Inflammation KW - Lipoprotein-associated phospholipase A(2) KW - Oxidative stress KW - Percutaneous coronary intervention KW - Polyunsaturated omega-3 fatty acids KW - Stable coronary disease SP - 434 EP - 9 JF - Nutrition, metabolism, and cardiovascular diseases : NMCD JO - Nutr Metab Cardiovasc Dis VL - 24 IS - 4 N2 - BACKGROUND AND AIMS: Increased consumption of omega-3 polyunsaturated fatty acids (PUFA) together with lifestyle measures and medications is recommended for the prevention of cardiovascular diseases. However, the exact mechanisms underlying observed benefits are not well defined. To this aim, we evaluated the effects of omega-3 PUFA in stable coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI) on lipoprotein associated phospholipase A2 (Lp-PLA2) mass and activity and their relation to oxidized low-density lipoproteins (oxy-LDL). METHODS AND RESULTS: In a prospective, double-blind, placebo-controlled, randomized study Lp-PLA2, oxy-LDL, myeloperoxidase and interleukin-6 were determined at baseline, 3-5 days and 30 days during administration of omega-3 PUFA 1 g/day (n = 30) or placebo (n = 24). Treatment with omega-3 PUFA resulted in reduction of Lp-PLA2 mass by 10.7%, activity by 9.3 (p = 0.026 for both) and oxy-LDL by 10.9% (p = 0.014) at 30 days, with no change in myeloperoxidase and interleukin-6. Compared with placebo, patients receiving omega-3 PUFA had lower Lp-PLA2 mass by 9.42%, activity by 9.2 (p = 0.041 for both) and oxy-LDL by 12.3% (p = 0.10) after one month, but not at 3-5 days. There were no correlations between Lp-PLA2 and both myeloperoxidase and oxy-LDL throughout the study. The multivariate model showed that only treatment with omega-3 PUFA and baseline myeloperoxidase levels were independent predictors of Lp-PLA2 mass changes at one month (R(2) = 0.37, P = 0.005). CONCLUSIONS: Administration of omega-3 PUFA can decrease Lp-PLA2 in patients with stable angina undergoing PCI. This novel effect may contribute to the benefits derived from omega-3 PUF. SN - 1590-3729 UR - https://www.unboundmedicine.com/medline/citation/24555913/Polyunsaturated_omega_3_fatty_acids_reduce_lipoprotein_associated_phospholipase_A_2__in_patients_with_stable_angina_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0939-4753(13)00259-7 DB - PRIME DP - Unbound Medicine ER -